UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/072,540	02/08/2002	James Arthur Hoffmann	X-11368A	4243
25885 ELI LILLY & (7590 04/28/200 COMPANY	EXAMINER		
PATENT DIVI	SION	WEDDINGTON, KEVIN E		
P.O. BOX 6288 INDIANAPOLI	IS, IN 46206-6288	ART UNIT	PAPER NUMBER	
			1614	
			NOTIFICATION DATE	DELIVERY MODE
			04/28/2008	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patents@lilly.com

		Application No.	Applicant(s)				
Office Action Summary		10/072,540	HOFFMANN, JAMES ARTHUR				
		Examiner	Art Unit				
		Kevin E. Weddington	1614				
The MA Period for Reply	ILING DATE of this communication app	pears on the cover sheet with the	correspondence ad	idress			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)⊠ Respons	ive to communication(s) filed on <u>07 D</u>	ecember 2007					
2a)⊠ This action	· · ·	action is non-final.					
<i>′</i> =							
·	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
0,0000 111	addendance with the practice ander 2		00 0.0. 210.				
Disposition of Cla	nims						
4)⊠ Claim(s)	☑ Claim(s) <u>35-54</u> is/are pending in the application.						
4a) Of the	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)☐ Claim(s)	5) Claim(s) is/are allowed.						
6)⊠ Claim(s))⊠ Claim(s) <u>35-54</u> is/are rejected.						
7) Claim(s)	is/are objected to.						
8) Claim(s)	are subject to restriction and/o	r election requirement.					
Application Pape	rs						
9)□ The spec	ification is objected to by the Examine	ır					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
•	may not request that any objection to the						
	nent drawing sheet(s) including the correct			FR 1 121(d)			
	or declaration is objected to by the Ex		-	, ,			
Priority under 35							
<u> </u>	•	muiamitu um dan 35 H.C.C. \$ 440/a	.\ (d\ o v (f\				
•	dgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a	i)-(a) or (ī).				
·— <u> </u>	 a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 						
<u>=</u>							
	3. Copies of the certified copies of the priority documents have been received in this National Stage						
· ·	application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)		_					
1) Notice of References Cited (PTO-892) A) Interview Summary (PTO-413) Paper No(s)/Mail Date							
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application							
Paper No(s)/Mail Date 6) Other:							

Art Unit: 1614

Claims 35-54 are presented for examination.

Applicant's response filed December 7, 2007 has been received and entered.

Accordingly, the rejection made under obviousness-type double patenting over U.S. Patent No. 6,358,924 as set forth in the previous Office action dated June 22, 2007 at pages 2-3 is hereby withdrawn because the applicant filed a terminal disclaimer.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 35-54 are again rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

This is a written description rejection.

A lack of adequate written description issue arises if the knowledge and level of skill in the art would not permit one skilled in the art to immediately envisage the product claimed from the disclosed process. See, e.g., Fujikawa v. Wattanasin, 93 F.3d 1559, 1571, 39 USPQ2d 1895, 1905 (Fed. Cir. 1996) (a "laundry list" disclosure of every possible moiety does not constitute a written description of every species in a

genus because it would not "reasonably lead" those skilled in the art to any particular species); In re Ruschig, 379 F.2d 990, 995, 154 USPQ 118, 123 (CCPA 1967).

An applicant may also show that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics which provide evidence that applicant was in possession of the claimed invention, i.e., complete or partial structure, other physical and/or chemical properties, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics.

In particular, the specification as original filed fails to provide sufficient written bases of any of the agents demonstrating wherein possession of use of the broad terms:

GLP-1, GLP-1 analogs and GLP-1 derivatives. The mere fact that Applicant may have discovered one type of GLP-1 compound, GLP-1 analog or GLP-1 derivatives is not sufficient to claim the entire genus.

The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406.

A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. The disclosure of only one species encompassed within a genus adequately describes a claim directed to that genus only if the disclosure "indicates that the patentee has invented species sufficient to constitute the gen[us]."

Although claims 37-46 lists specific examples of compounds that are GLP-1, GLP-1 analogs and GLP-1 derivatives, and claims 35 and 36 are directed to a variety of compounds with the functional description of being known as GLP-1. GLP-1 analogs and GLP-1 derivatives.

Again, applicant only shows a stable pharmaceutical formulation comprising only GLP-1, Val-GLP-1(7-37).

Undue experimentation is needed to shows that all GLP-1 compounds, GLP-1 analogs and GLP-derivatives were stable in the instant formulation.

The rejection made under 35 USC 112, first paragraph (written description) is adhered to.

Claims 35-54 are not allowed.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kevin E. Weddington whose telephone number is (571)272-0587. The examiner can normally be reached on 12:30 pm-9:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on (571)272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1614

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Kevin E. Weddington Primary Examiner

Art Unit 1614

/Kevin E. Weddington/

Primary Examiner, Art Unit 1614